US FDA inspection at Pithampur facility ends with 2 procedural observations

Business Updates View source PDF Explain this filing

RUBICON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.6%Reaction day

₹1312.10

prior close

₹1330.50

announcement price

After-mkt

timing

Nifty Microcap 250market+0.2%+3.4% vs market

Pharmaceuticals peers, median of 164sector-0.5%+4.1% vs sector

On the reaction day the stock moved 3.4 pts more than Nifty Microcap 250 and 4.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+2.1

15m

+3.2

30m

+3.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.6+0.2+3.4-0.5+4.1

Next day

+5.5-0.5+6.0-0.7+6.2

+6.8-2.5+9.4-1.7+8.5

+7.3-0.6+7.9-1.3+8.6

+9.0+0.7+8.3-0.5+9.5

+9.7+0.9+8.9+0.2+9.5

+10.6+0.5+10.1+0.4+10.1

15d

+20.0-0.2+20.2-1.4+21.4

+17.0+2.9+14.1-1.7+18.7

+33.5+5.0+28.6+1.2+32.3

+21.5+3.7+17.8+0.4+21.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

US FDA inspected Rubicon Research's Pithampur facility from June 29 to July 3, 2026, the first inspection since its acquisition last year. A Form 483 with 2 procedural observations was issued, none related to data integrity. The company plans to address these with the regulator and remains on track to start commercial operations at the facility from Q1 calendar year 2027.

Likely market impact

Mildly positive - only 2 procedural observations, no data integrity issues, and company is confident of addressing them. Supports planned Q1 2027 ramp-up.